Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with...
Read MoreDec 6, 2024
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with...
Read MoreDec 6, 2024
The ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol is associated with diabetic kidney disease: A cross-sectional study 1. Each one-unit increase in Non-High-Density Lipoprotein...
Read MoreDec 5, 2024
1. Compared to the general population, survivors of childhood cancer had a greater association...
Read MoreDec 5, 2024
1. Isaclimab significantly improved disease activity at 150 mg and 600 mg doses. 2. Adverse events...
Read MoreDec 5, 2024
1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and...
Read MoreDec 4, 2024
1. Patients in the MGT group reported a significantly greater progression-free survival than those...
Read MoreDec 4, 2024
1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2....
Read MoreDec 3, 2024
1. Progression-free survival at 12 months was 79% with nivolumab/ipilimumab vs 21% with...
Read MoreDec 1, 2024
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with...
Read MoreNov 30, 2024
1. A history of endometriosis and uterine fibroids in women was associated with a greater risk of...
Read MoreNov 28, 2024
1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free...
Read MoreNov 27, 2024
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read MoreNov 27, 2024
1. In this randomized controlled trial of patients with heart failure and mildly decreased or...
Read MoreNov 26, 2024
1. Three unrelated children were found to have a de novo deletion in the long non-coding RNA...
Read MoreNov 26, 2024
1. After almost 10 years of follow-up, adjuvant dabrafenib and trametinib improved relapse-free...
Read MoreNov 26, 2024
1. Median PFS was 6.6 months in the switch maintenance group and 3.5 months in the control group...
Read MoreNov 26, 2024
1. In this randomized controlled trial, among adults diagnosed with chronic myeloid leukemia...
Read MoreNov 26, 2024
1. In this randomized controlled trial, total hip replacement (THR) was superior to resistance...
Read MoreNov 23, 2024
1. In this prospective study, the use of a leadless pacemaker that received wireless communication...
Read MoreNov 23, 2024
1. In this randomized controlled trial, among patients with localized prostate cancer,...
Read More